NRD
CRNX icon

Nebula Research & Development’s Crinetics Pharmaceuticals CRNX Stock Holding History

Nebula Research & Development’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,727
Closed -$344K – 937
2024
Q3 		$344K Buy
+6,727
New +$347K 0.04% 673

Other funds holding CRNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nebula Research & Development's CRNX Position: Q4 2024 in Review

Nebula Research & Development sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2024, closing a stake of 6,727 shares — an estimated $344K sold.

Nebula Research & Development first reported a position in CRNX in Q3 2024 and held it in 1 quarter. The position peaked at $344K in Q3 2024. 247 funds tracked by Wall St. Rank hold CRNX as of Q4 2024.

  • Nebula Research & Development reported no remaining Crinetics Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 6,727 Crinetics Pharmaceuticals shares in Q4 2024, an estimated $344K.
  • Nebula Research & Development first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Nebula Research & Development's Crinetics Pharmaceuticals position peaked at $344K in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.